In Brief: Zanubrutinib (Brukinsa) for CLL or SLL
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1670e ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa), which was previously approved by the FDA for treatment of mantle cell lymphoma, Waldenström's macroglobulinemia, and relapsed or refractory marginal zone lymphoma, has now been approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults. The BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) were approved earlier for treatment of CLL and SLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). In Brief: Zanubrutinib (Brukinsa) for CLL or SLL. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670e
Vancouver
In Brief: Zanubrutinib (Brukinsa) for CLL or SLL. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670e
BibTeX
@article{euvimed2023,
title = {In Brief: Zanubrutinib (Brukinsa) for CLL or SLL},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1670e}
}
EUVIMED